BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical

  October 7, 2024

   · 

  2 min read
• Press Releases

  Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney

  October 7, 2024

   · 

  3 min read
• Press Releases

  Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging

  October 7, 2024

   · 

  3 min read
• Press Releases

  Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board

  October 7, 2024

   · 

  5 min read
• Press Releases

  Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

  October 7, 2024

   · 

  13 min read
• Drug Development

  AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

  October 7, 2024

   · 

  12 min read
• 

  Regulatory

  Kezar’s Lupus Trial Paused After Four Patient Deaths

  The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.

  October 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Infectious disease

  J&J Discontinues Phase II Dengue Study as it Retreats from Infectious Disease

  J&J has recently pulled back from the infectious diseases space, including winding down R&D activity in this area in August 2023.

  October 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

  October 7, 2024

   · 

  7 min read
• Press Releases

  Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

  October 7, 2024

   · 

  7 min read